文献速递白血病造血干细胞移植与细胞治疗

酪氨酸激酶抑制剂治疗中Ph+急性淋巴细胞白血病患者接受BCR-ABL特异性T细胞治疗

BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
PubMed 文献 · Blood · 2016-12-07

研究探讨体外扩增/致敏p190BCR-ABL特异性T细胞并过继回输治疗复发Ph+ ALL的可行性。从患者和健康供者制备具有抗白血病活性的临床级BCR-ABL特异性细胞毒性T淋巴细胞(CTL),治疗3例Ph+ ALL患者,除1例因血液学复发治疗者出现II级皮肤移植物抗宿主病外未见输注后毒性,所有患者均获分子学或血液学完全缓解(CR)。

要点

  • 可从Ph+ ALL患者和健康供者制备临床级p190BCR-ABL特异性CTL
  • 3例Ph+ ALL患者接受自体或异基因p190BCR-ABL特异性CTL治疗
  • 除1例血液学复发者出现II级皮肤GVHD外,未见输注后毒性

核心结论

  • p190BCR-ABL特异性CTL能够在体内控制治疗难治性Ph+ ALL,支持在Ph+ ALL中开发BCR-ABL CTL过继免疫治疗策略。

研究设计与样本

  • 研究体外用负载p190BCR-ABL肽(源自BCR-ABL连接区及可变剪接)的树突状细胞刺激扩增/致敏p190BCR-ABL特异性T细胞,并过继回输至复发患者。
  • 从Ph+ ALL患者和健康供者制备具有抗白血病活性的临床级BCR-ABL特异性细胞毒性T淋巴细胞(CTL)。
  • 治疗3例Ph+ ALL患者,回输自体或异基因p190BCR-ABL特异性CTL。

主要发现

  • 3例Ph+ ALL患者接受自体或异基因p190BCR-ABL特异性CTL治疗,除1例因血液学复发治疗者出现II级皮肤移植物抗宿主病外,未见输注后毒性。
  • 所有患者在T细胞治疗后、骨髓中出现p190BCR-ABL特异性T细胞后,均达到分子学或血液学完全缓解(CR)。

关键数值与推荐

  • 3例Ph+ ALL患者接受自体或异基因p190BCR-ABL特异性CTL治疗。
  • 1例因血液学复发治疗的患者出现II级皮肤移植物抗宿主病。
  • 所有患者达到分子学或血液学完全缓解(CR)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the emergence of bone marrow (BM)-resident p190BCR-ABL-specific T lymphocytes has been correlated with hematologic and cytogenetic remissions in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) undergoing maintenance tyrosine-kinase inhibitor treatment, little is known about the possibility of culturing these cells ex vivo and using them in T-cell therapy strategies. We investigated the feasibility of expanding/priming p190BCR-ABL-specific T cells in vitro by stimulation with dendritic cells pulsed with p190BCR-ABL peptides derived from the BCR-ABL junctional region and alternative splicing, and of adoptively administering them to patients with relapsed disease. We report on the feasibility of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity, from Ph+ ALL patients and healthy donors. We treated 3 patients with Ph+ ALL with autologous or allogeneic p190BCR-ABL-specific CTLs. No postinfusion toxicity was observed, except for a grade II skin graft-versus-host disease in the patient treated for hematologic relapse. All patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emergence of p190BCR-ABL-specific T cells in the BM. Our results show that p190BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph+ ALL in vivo, and support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph+ ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Comoli P, Basso S, Riva G, et al. BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. Blood. 2016. PMID: 27927646. doi:10.1182/blood-2016-07-731091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。